From GlobeNewswire:

Vincerx Pharma, Inc. has announced promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for the treatment of relapsed/refractory lymphoma. Tumor response was observed in patients with peripheral T-cell lymphoma (PTCL) and double-hit diffuse large B-cell lymphoma (DH-DLBCL). The lead drugs from their VersAptx platform, VIP236 and VIP943, are progressing through dose-escalation studies, with early clinical data expected in 2024. Enitociclib is a highly selective CDK9 inhibitor currently being evaluated in a Phase 1 trial in collaboration with the National Institutes of Health. VIP236 and VIP943 are first-in-class drugs also in Phase 1 trials.



Read more: Vincerx Pharma Announces Compelling Clinical Efficacy of